Biochip

Archer Miniaturises Biochip gFET Chip Design

Retrieved on: 
Friday, March 15, 2024
Semiconductor, Health, Technology, Other Technology, Other Health, Hardware, Biochip, Electronics, ASX, AXE, ANL

The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology.

Key Points: 
  • The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology.
  • The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm.
  • This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing.
  • Commenting on the miniaturisation of the Biochip gFET chip design, Dr Mohammad Choucair, CEO of Archer, said, “The significant reduction in the size of the Biochip was a great achievement by the Archer team.

Archer Demonstrates Multiplexing Readout for Its Advanced Biochip gFET

Retrieved on: 
Wednesday, November 1, 2023
ASX, Acquisition, Software, Biochip, AXE, Automation, Medical imaging, Mobile phone, Archery

SYDNEY, Australia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”), a semiconductor company advancing the quantum computing and medical diagnostics industries, has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (“gFET”) device.

Key Points: 
  • Archer Materials has demonstrated multiplexing readout for its Biochip by integrating its advanced gFET sensors with newly developed hardware and software that analyse multiple liquid samples on a chip at once.
  • SYDNEY, Australia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Archer Materials Limited (“Archer”, the “Company”, “ ASX: AXE ”), a semiconductor company advancing the quantum computing and medical diagnostics industries, has demonstrated multiplexing readout for its advanced Biochip graphene field effect transistor (“gFET”) device.
  • Archer confirmed single-device multiplexing using four advanced gFETs as sensors, which were integrated into the Archer advanced Biochip platform that was announced on 14 September 2023.
  • Archer designed and developed the new hardware and software systems to readout the signal from the four advanced gFET sensors at once on a single chip.

ACROBiosystems Aneuro Partners with Diagnostic Biochips to Accelerate Neuroscience Drug Discovery

Retrieved on: 
Wednesday, June 14, 2023
Cloud, Huntington's disease, Brain, ALS, Pathology, Global health, Medicine, Research, DSM-IV codes, Multiple sclerosis, PFF League, Marketing, Acquisition, Parkinson's disease, Nature, Electrophysiology, Biochip, Alzheimer's disease, Medical imaging

BASEL, Switzerland, June 14, 2023 /PRNewswire/ -- ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.

Key Points: 
  • BASEL, Switzerland, June 14, 2023 /PRNewswire/ -- ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.
  • Together, two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialization.
  • Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network.
  • Acro Certify is ACROBiosystems' new business model designed to help partners reach global markets and build a global brand presence.

$307.3 Billion Worldwide Clinical Laboratory Services Industry to 2027 - Featuring Abbott Laboratories, bioMerieux, Charles River Laboratories and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Science, Health, Other Science, Other Health, Patient, Infection, COVID-19, Diagnosis, Computer, Diabetes, Coronavirus, Conditional sentence, POC, Incidence, Cancer, Biochip, Pharmaceutical industry, Growth

The global clinical laboratory services market size reached US$ 217.4 Billion in 2021.

Key Points: 
  • The global clinical laboratory services market size reached US$ 217.4 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 307.3 Billion by 2027, exhibiting a CAGR of 5.94% during 2021-2027.
  • Clinical laboratory services rely on technologically advanced devices and testing kits to reduce human error and provide reliable results.
  • Besides this, a significant rise in the number of novel drug candidates in clinical trials is anticipated to drive the demand for clinical laboratory services.

Insights on the Clinical Laboratory Services Global Market to 2027 - Rising Awareness About Early Diagnosis Among Individuals Drives Growth

Retrieved on: 
Thursday, December 22, 2022
Charles River Laboratories, Patient, Infection, Becton, Dickinson and Company headquarters, COVID-19, Diagnosis, Computer, Diabetes, Coronavirus, Siemens, Abbott Laboratories, Illumina, Inc., Conditional sentence, POC, Incidence, Cancer, Biochip, Thermo Fisher Scientific, Quest Diagnostics, Pharmaceutical industry, Fine chemical, Potash, Growth

The global clinical laboratory services market size reached US$ 217.4 Billion in 2021.

Key Points: 
  • The global clinical laboratory services market size reached US$ 217.4 Billion in 2021.
  • Clinical laboratory services rely on technologically advanced devices and testing kits to reduce human error and provide reliable results.
  • What has been the impact of COVID-19 on the global clinical laboratory services market?
  • What is the structure of the global clinical laboratory services market and who are the key players?

Top US MEMS Semiconductor Foundry Raises $30m Series C Financing

Retrieved on: 
Tuesday, November 8, 2022
Cloud, CHIPS, Novo, Glass, Growth, Life, Economics, ITAR, Biochip, Entrepreneurship, Genomics, Microelectromechanical systems, Silicon, Partnership, Cloud computing, Internet of things, Investment, Leadership, MEMS, Solution, IOT, Technology, Airline, Renewable energy, Borosilicate glass, Medical imaging, Cerium, Atom (character)

SANTA BARBARA, Calif., Nov. 8, 2022 /PRNewswire-PRWeb/ -- Atomica Corp, a leader of micro electro-mechanical systems (MEMS), today announced a $30 million Series C financing. The round was funded by Cerium Technology Ventures, Novo Tellus Capital Partners, and St. Cloud Capital. The new financing allows Atomica to expand its foundry capabilities, advance MEMS technologies, and support domestic production of biochips, sensors, and photonic circuits.

Key Points: 
  • Cloud Capital
    SANTA BARBARA, Calif., Nov. 8, 2022 /PRNewswire-PRWeb/ -- Atomica Corp , a leader of micro electro-mechanical systems (MEMS), today announced a $30 million Series C financing.
  • The new financing allows Atomica to expand its foundry capabilities, advance MEMS technologies, and support domestic production of biochips, sensors, and photonic circuits.
  • Atomica is the leading US MEMS foundry, partnering with innovative system-vendors and fabless device firms globally to bring new technologies to life.
  • These investments aid our efforts to grow and protect domestic U.S. manufacturing of MEMS and related semiconductor technologies."

Global Biochips Market Research Report 2022: Market to Surpass $25+ Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Technology, Other Technology, DNA microarray, Protein, Prevalence, Growth, CAGR, Biotechnology, Coronavirus, Cancer, Technology, Biochip, Incidence, Fluorophore, Nanotechnology, COVID-19, Pet, Speciality chemicals, Video game, Vaccine, Pharmaceutical industry

Biochips (for example, lab-on-a-chip) thus serve as a mini laboratory where multiple analytes from a single sample are tested simultaneously.

Key Points: 
  • Biochips (for example, lab-on-a-chip) thus serve as a mini laboratory where multiple analytes from a single sample are tested simultaneously.
  • This segment currently accounts for a 30.6% share of the global Biochips market.
  • The U.S. Market is Estimated at $6.3 Billion in 2022, While China is Forecast to Reach $2.4 Billion by 2026
    The Biochips market in the U.S. is estimated at US$6.3 Billion in the year 2022.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$516.1 Million Billion by the year 2026.

Global Biochips Market Report 2022: Increasing Adoption of Personalized Medicine Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Biotechnology, Health Technology, Health, Adoption, POC, Revenue, Prevalence, Miniaturization, Application, Growth, Diabetes, USD, Cancer, Biochip, Technology, Diagnosis, CAGR, Substrate (materials science), Genomics, DNA, Medicine, Proteomics, Awareness, Lists of countries and territories, Drug discovery, Conditional sentence, Pharmaceutical industry

The global biochip market size is expected to reach USD 34.35 Billion in 2030 and register a revenue CAGR of 11.5% over the forecast period, according to the latest report.

Key Points: 
  • The global biochip market size is expected to reach USD 34.35 Billion in 2030 and register a revenue CAGR of 11.5% over the forecast period, according to the latest report.
  • In addition, the increasing adoption of personalized medicine and point-of-care (POC) testing is estimated to propel market growth.
  • Increasing application of biochips in proteomics, genomics, and drug discovery coupled with growth in the field of personalized medicine is projected to fuel the market growth.
  • In the past two decades, the adoption of biochip technology has increased significantly in the field of healthcare and medicine.

Organs-On-Chips Market size worth $ 300.89 Million, Globally, by 2028 at 36.90% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, July 5, 2022
Interactivity, EMT, Research, NGS, Molecular diagnostics, Metal, Defense, Transport, Gene expression, Consumables, SME, VMI, DNA microarray, Data collection, Energy, Geography, Biochip, Information and communications technology, New product development, Building & Construction Trades Council v. Associated Builders & Contractors of Massachusetts/Rhode Island, Inc., Time, Biotechnology, Mineral, Medical device, Ministry of Energy (Power Division), High-throughput screening, Key, National Virus Reference Laboratory, Polymerase, Information, Validation, PCR, Market research, DNA sequencing, Polymerase chain reaction, Automatic meter reading, DNA profiling, R, Drug discovery, Automotive industry, DNA, Reagent, Fine chemical, Hospital, Software, Medication, Mining, Technology, Health care, Microsoft Excel, Chemical substance

JERSEY CITY, N.J., July 5, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Organs-On-Chips Market" By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Application (Physiological Model Development, Drug Discovery, and Toxicology Research), By Offering (Products and Services), By Type (Liver, Heart, Lung, Kidney), and By Geography. According to Verified Market Research, the Organs-On-Chips Market size was valued at USD 21.36 Million in 2020 and is projected to reach USD 300.89 Million by 2028, growing at a CAGR of 36.90% from 2021 to 2028.

Key Points: 
  • VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market.
  • VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.
  • Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers.
  • Verified Market Research provides advanced analytical research solutions while offering information enriched research studies.

Global Drug Discovery Technologies Market Research Report to 2027 - Patent Expiries of Several Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 6, 2022
Health, Pharmaceutical, Molecular biology, COVID-19, Decision-making, Investment, Strategic management, Drug discovery, Compound annual growth rate, Business Growth Fund, Value, Biotechnology, USD, Use, Nanotechnology, Certification, Market share analysis, Genomics, R, End user, CAGR, Growth, Acquisition, Customer support, Pharmaceutical industry, Retail, Medical device, Fine chemical, Biochip, Bioinformatics, Technology

What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Discovery Technologies Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Discovery Technologies Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Drug Discovery Technologies Market?
  • What is the market share of the leading vendors in the Global Drug Discovery Technologies Market?
  • What modes and strategic moves are considered suitable for entering the Global Drug Discovery Technologies Market?